Mary Anne Jackson

TL;DR: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.

TL;DR: This evidence-based clinical practice guideline is a revision of the 2004 acute otitis media (AOM) guideline from the American Academy of Pediatrics (AAP) andAmerican Academy of Family Physicians and provides recommendations to primary care clinicians for the management of children from 6 months through 12 years of age with uncomplicated AOM.

TL;DR: The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effects of prophylaxis on wheezing, and palivZumab-resistant RSV isolates.

TL;DR: Recommendations for immunoprophylaxis have been updated in an effort to ensure optimal balance of benefit and cost from this expensive intervention and are consistent with the 2009 Red Book recommendations.

TL;DR: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment.